Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
HONG KONG, HK / ACCESS Newswire / May 18, 2026 / Sequencio Therapeutics, a subsidiary of CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences", Stock Code:0775) today announced the appointment of Emily Tan as Chief Operating Officer. A 30-year ...
What CK Life Sciences Int'l. (Holdings) (SEHK:775) investors are watching now With no fresh headline event driving CK Life Sciences Int'l. (Holdings) (SEHK:775) today, the stock’s recent performance and current profitability profile are front of mind for investors assessing how the business is positioned. See our latest analysis for CK Life Sciences Int'l. (Holdings). At a share price of HK$0.85, CK Life Sciences Int'l. (Holdings) has posted a 30 day share price return of 2.41% and a 1 year...
Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for up to approximately $12.5
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.